Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.
| Publicado en: | Cancer Chemotherapy & Pharmacology Vol. 93; no. 4; pp. 329 - 340 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Apr2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=176144878&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 176144878 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 03445704 NO9 jtl: Cancer Chemotherapy & Pharmacology issn: 03445704 maglogo: N pubinfo: dt: Apr2024 vid: 93 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 176144878 173908759 10.1007/s00280-023-04613-9 176144878 ppf: 329 ppct: 11 formats: tig: atl: Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study. aug: au: Biesdorf, Carla Guan, Xiaowen Siddani, Satya R. Hoffman, David Boehm, Nils Medeiros, Bruno C. Doi, Toshihiko de Jonge, Maja Rasco, Drew Menon, Rajeev M. Polepally, Akshanth R. affil: Clinical Pharmacology, AbbVie Inc., 1 North Waukegan Road, Bldg. AP31-3, 60064, North Chicago, IL, USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|